These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28291640)

  • 21. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
    Sørensen AL; Skov V; Kjær L; Bjørn ME; Eickhardt-Dalbøge CS; Larsen MK; Nielsen CH; Thomsen C; Rahbek Gjerdrum LM; Knudsen TA; Ellervik C; Overgaard UM; Andersen CL; Hasselbalch H
    Blood Adv; 2024 Oct; 8(20):5416-5425. PubMed ID: 39163611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
    Desterro J; McLornan DP; Curto Garcia N; O'Sullivan J; Alimam S; Keohane C; Woodley C; Francis Y; Kordasti S; Radia DH; Harrison CN
    Br J Haematol; 2019 Aug; 186(4):561-564. PubMed ID: 31090926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
    Andersen CL; McMullin MF; Ejerblad E; Zweegman S; Harrison C; Fernandes S; Bareford D; Knapper S; Samuelsson J; Löfvenberg E; Linder O; Andreasson B; Ahlstrand E; Jensen MK; Bjerrum OW; Vestergaard H; Larsen H; Klausen TW; Mourits-Andersen T; Hasselbalch HC
    Br J Haematol; 2013 Aug; 162(4):498-508. PubMed ID: 23758082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
    Masarova L; Yin CC; Cortes JE; Konopleva M; Borthakur G; Newberry KJ; Kantarjian HM; Bueso-Ramos CE; Verstovsek S
    Exp Hematol Oncol; 2017; 6():30. PubMed ID: 29152412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
    Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
    Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
    Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
    Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
    Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
    Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
    Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
    Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
    Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
    Löfvenberg E; Wahlin A
    Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera.
    Stasi R; Brunetti M; Bussa S; Venditti A; Del Poeta G; Conforti M; Scimò MT; Cudillo L; Adorno G; Cecconi M; Amadori S; Pagano A
    J Intern Med; 1997 Aug; 242(2):143-7. PubMed ID: 9279291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
    Penka M; Schwarz J; Ovesná P; Hlusí A; Korístek Z; Doubek M; Dulícek P; Pospísilová D; Kissová J; Buliková A; Pavlík T;
    Vnitr Lek; 2010 Jun; 56(6):503-12. PubMed ID: 20681462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
    Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.